Pharmacocinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 837-842

  Passe, P ^a   Delepine, N ^a   Arnaud, P ^a   Urien, S ^b   Delepine, G ^a   Traore F ^a   Desbois, J C ^a   Brion, F ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

Auto induction model; Ifosfamide; Oncology; Pharmacokinetics

Indexed keywords

IFOSFAMIDE; MESNA; ONDANSETRON; ALKYLATING AGENT;

ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MODEL; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; ADOLESCENT; ADULT; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BONE TUMOR; CHILD; COMPARATIVE STUDY; MATHEMATICS; METABOLIC CLEARANCE RATE; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IFOSFAMIDE; MALE; MATHEMATICS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0032589070     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sladek NE. Metabolism of oxazaphosphorine, Pharmac Ther 37: 301-55, 1988.
2. The Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 64: 2010-13, 1989.
3. Chang TKH, Weber GF, Crepi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosfamide by cytochrome P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-37, 1993.
4. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson DJ, Beaune PH, Idle JR: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-63, 1994.
5. Manthey CL, Landkamer GJ, Sladek NE: Identification of the mouse aldehyde deshydrogenases important in aldophosphamide detoxification. Cancer Res 50: 4991-5002, 1990.
6. Dockham PA, Lee MO, Sladek NE: Identification of human liver aldehyde deshydrogenases that catalyse the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 43: 2453-69, 1992.
7. Highlet MS, Momerency G, Van Cauwenberghe K, Van Oosterom AT, De Bruijn EA, Maes RA, Blake P, Mansi J, Harper PG: Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in human. Drug Metab Disp 23: 433-437, 1995.
8. Allen LM, Creaven PJ: Pharmacokinetics of ifosfamide. Clin Pharmacol Ther 17-4: 492-8, 1975.
9. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with lung cancer. Cancer Res 49: 753-7, 1989.
10. Nelson RL, Allen LM, Creaven PJ: Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther 19: 365-70, 1977.
11. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ: Fractioned ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmac 30: 725-32, 1990.
12. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR: Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53: 3758-64, 1993.
13. Wagner T, Ehninger G: Self-induction of cyclophosphamide and ifosfamide metabolism by repeated high-dose treatment. Contr Oncol 26: 69-75, 1987.
14. Kurowski V, Cerny T, Küpfer A, Wagner T: Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117 (Suppl. IV): S148-S153, 1991.
15. Prasad VK, Corlet SA, Abaasi K, Heney D, Lewis I, Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother Pharmacol 34: 447-9, 1994.
16. Boddy AV, Cole M, Person DJ, Idle JR: The kinetics of autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chem Pharmacol 36: 53-60, 1995.
17. Levy RH, Dumain MS, Cook JL. Time-dependent kinetics. V: Time course of drug levels during enzyme induction (one compartment model). J Pharma Biopharm 7: 6, 1979.
18. Pitlick WH, Levy RH, Troupin AS, Green JR. Pharmacokinetics model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65: 462-3, 1975.
19. Urien S: MicroPharm-K, a Microcomputer Interactive Program for the Analysis and Simulation of Pharmacokinetic Processes. Pharmaceutical Res 12: 1225-30, 1995.
20. Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ: The pharmacokinetics of ifosfamide given as short and long intravenous infusion in cancer patients. Br J Clin Pharmac 31: 77-81, 1991.
21. Wagner T, Drings P: Pharmacokinetics and Bioavailability of oral ifosfamide. Drug Res 36 (I), Nr. 5: 878-880, 1986.
22. Chang TK, Yu L, Maurel P, Waxman DJ: Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57(10): 1946-54, 1997.